___

• 1. Aman W, Mousa S, Shiha G, Mousa SA. Current status and future directions in the management of chronic hepatitis C, Virol J 2012;2;9:57. 2. Carrozzo M, Brancatello F, Dametto E et al. Hepatitis C virus-associated oral lichen planus: is geographical heterogeneity related to HLA-DR6? J Oral Pathol Med 2005;34(4):204-8. http://dx.doi.org/10.1111/j.1600-0714.2005.00303.x 3. Chainani-Wu N, Lozada-Nur F, Terrault N. Hepatitis C virus and lichen planus: a review, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98(2):171-83. http://dx.doi.org/10.1016/j.tripleo.2003.11.010 4. Dalekos GN, Christodoulou D, Kistis KG, Zervo EK, Hatzis J, Tsianos EV. A prospective evaluation of dermatological side effects during alpha inter- feron therapy for chronic viral hepatitis, Eur J Gastroenterol Hepatol 1998;10(11):933-9. http://dx.doi.org/10.1097/00042737-199811000-00006 5. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C, Hepatology 1997;26(3 Suppl 1):S112-21. http://dx.doi.org/10.1002/hep.510260720 6. Erbağcı Z. HCV enfeksiyonunun interferonla tedavisi sırasında ülserleşen lokalize liken planus, TURKDERM 1999;33(1):53-4. 7. Gencoglan G, İnanir İ, Sahin O, Gunduz K. Imiquimod 5 % cream for isolated lichen planus of the lip, J Dermatolog Treat 2011;22(1):55-9. http://dx.doi.org/10.3109/09546630903456367 8. Grossmann Sde M, Teixeira R, de Aguiar MC, do Carmo MA. Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin, Eur J Gastroenterol Hepatol 2008;20(7):702-6. http://dx.doi.org/10.1097/MEG.0b013e3282f1cc5d 9. Guijarro Guijarro B, López Sánchez AF, Hernández Vallejo G. Presence of lichen planus during a cour- se of interferon alpha-2a therapy for a viral chro- nic C hepatitis, Med Oral 2001;6(5):358-63. 10. Guner R, Keske S, Hasanoglu I, Tasyaran M. Pityriasis rosea associated with pegylated interfe- ron alpha and ribavirin treatment in a patient with chronic hepatitis C, Balkan Med J 2013;30(2): 253-4. http://dx.doi.org/10.5152/balkanmedj.2012.109 11. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagno- sis, management and malignant transformation, J Oral Sci 2007;49(2):89-106. http://dx.doi.org/10.2334/josnusd.49.89 12. Itin PH, Schiller P, Gilli L, Buechner SA. Isolated lichen planus of the lip, Br J Dermatol 1995;132(6): 1000-2. http://dx.doi.org/10.1111/j.1365-2133.1995.tb16963.x 13. Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C, Chemotherapy 2005;51(2-3):167-9. http://dx.doi.org/10.1159/000085626 14. Lavanchy D. The global burden of hepatitis C, Liver Int 2009;29(Suppl 1):S74-81. http://dx.doi.org/10.1111/j.1478-3231.2008.01934.x 15. Li Z, Zhang Y, An J, Feng Y, Deng H, Xiao S, Ji F. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C, J Clin Virol 2014;60(3):190-5. http://dx.doi.org/10.1016/j.jcv.2014.04.012 16. Nagao Y, Kawaguchi T, Ide T, Kumashiro R, Sata M. Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C, Int J Mol Med 2005;15(2):237- 41. 17. Petruzzi M, De Benedittis M, Pastore L, Pannone G, Grassi FR, Serpico R. Isolated lichen planus of the lip, Int J Immunopathol Pharmacol 2007;20(3): 631-5. 18. Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holtermüller KH. Exacerbation of lichen pla- nus during interferon alpha-2a therapy for chro- nic active hepatitis C, Gastroenterology 1993;104(3): 903-5. 19. Wenzel J, Scheler M, Proelss J, Bieber T, Tüting T. Type I interferon-associated cytotoxic inflammati- on in lichen planus, J Cutan Pathol 2006;33(10): 672-8. http://dx.doi.org/10.1111/j.1600-0560.2006.00527.x 20. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alpha-2a in patients with chronic hepatitis C, N Engl J Med 2000;343(23):1666-72. http://dx.doi.org/10.1056/NEJM200012073432301